| Advertisement |
June 2 (UPI) -- Researchers in the Netherlands have started a clinical trial to discover if a commonly used psychiatric drug can boost the fitness of healthy cells in the gut to prevent the development of bowel cancer. Worldwide Cancer Research said Wednesday that the trial will recruit patients with a genetic mutation that means they are 100% certain to develop bowel cancer in their lifetime unless the entire bowel is removed.
Advertisement
Lithium, a commonly used drug for the treatment of several psychiatric disorders, will be used in the trial.
Researchers found, according to a study published Wednesday in the journal Nature, that intestinal stem cells with mutations to the APC gene have been shown to have a competitive advantage over their healthy counterparts and frequently outcompete them, leading to unrestricted growth and cancer.
The mutant stem cells actively emit signals that sabotage the function of healthy stem cells in the gut.
"We have uncovered the very first steps in the development of bowel cancer. We found that following the occurrence of a mutation in a key gene that regulates stem cells in the intestine, these cells turn into cheaters that actively suppress the normal cells in the environment," senior study author Louis Vermeulen said in a press release.
"Our findings indicate that cells on their way to a full malignancy can actively suppress the stem cells in the vicinity to gain a competitive edge. This is a concept we refer to as supercompetition," said Vermeulen, group leader at the Center for Experimental Molecular Medicine at Amsterdam UMC.
Researchers discovered that lithium prevented mutant stem cells from taking over and forming tumors in mice by rendering healthy stem cells insensitive to the damaging signals.
A clinical trial funded by the Dutch Cancer Society will test the effect of lithium on bowel cancer development in individuals with familial adenomatous polyposis, an uncommon genetic syndrome that results in mutations in APC genes.
Without treatment, nearly all those with FAP will develop bowel cancer between the ages of 35 and 45, according to researchers.
The trial will recruit 10 young adult patients with FAP and will observe the patients before, during and after treatment with lithium for a total of 18 months.
"Our clinical trial may reveal that lithium can be used to prevent cancer development in FAP individuals," said Sanne van Neerven, a doctoral student who conducted the research.
"But what is also important is that this trial can establish a proof of concept that manipulating competition between mutant cells and normal cells can be manipulated in such a way that the healthy cell outcompete the mutant cells," van Neerven said.
Worldwide Cancer Research Chief Executive Dr. Helen Rippon called the new findings a huge breakthrough in understanding how bowel cancer develops.
"Around 1% of bowel cancers are caused by [FAP]. This may seem like a small number, but in [Britain] alone this means that over 400 people are diagnosed with bowel cancer caused by FAP every year," she said.
"The only treatment option available for people with FAP is major surgery to remove the entire colon, which can be life altering and unfortunately cannot guarantee that cancer won't develop," Rippon said.
She added that the launch of the trial could offer "real hope" to people for a simple solution to preventing bowel cancer in the future.
In Britain, bowel cancer affects 43,000 people, colorectal cancers are the third highest most commonly diagnosed in the United States. Just over half the people diagnosed with bowel cancer survive the disease for 10 years or longer.
